A Phase I, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Saroglitazar Following a Single Oral Dose of [14C]-Saroglitazar Magnesium in Healthy Male Subjects
Latest Information Update: 07 Jun 2021
At a glance
- Drugs Saroglitazar (Primary)
- Indications Dyslipidaemias; Hypertriglyceridaemia; Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Polycystic ovary syndrome; Primary biliary cirrhosis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Zydus Discovery DMCC
- 11 Nov 2019 Status changed from recruiting to completed.
- 04 Oct 2019 New trial record